Affinity Asset Advisors, LLC
13F Reported Value
ⓘ$2.2B
incl. option notional
Equity Holdings
ⓘ$2.0B
Option Notional
ⓘ$167.6M
$55.1M puts / $112.6M calls
Holdings
113
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Affinity Asset Advisors, LLC disclosed 113 positions worth $2.2B in its Form 13F-HR for Q2 2026 — $2.0B in common stock plus $167.6M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ROIV (Roivant Sciences Ltd.) at 6.5% of the equity portfolio, followed by $APGE and $SYRE. During the quarter the fund opened 23 new positions and exited 15 — including a new stake in $TRAX and a full exit from $SPY. The portfolio is most concentrated in Healthcare (98.5% of disclosed assets). All figures are sourced directly from Affinity Asset Advisors, LLC’s Form 13F-HR filing with the SEC under CIK 1773195.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$132.7M3,750,000 sh - —
Quality
$131.0M987,000 sh - —
Quality
$113.6M1,279,134 sh - 24.0
Quality
$96.3M1,595,000 sh - —
Quality
$96.2M5,250,000 sh - 39.4
Quality
$69.3M650,000 sh - $61.9M185,000 sh
- —
Quality
$58.9M1,125,000 sh - —
Quality
$56.2M590,000 sh - 48.4
Quality
$55.8M826,109 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Roivant Sciences Ltd.$ROIV | — | $132.7M | 3,750,000 |
 Apogee Therapeutics, Inc.$APGE | — | $131.0M | 987,000 |
 Spyre Therapeutics, Inc.$SYRE | — | $113.6M | 1,279,134 |
 Xenon Pharmaceuticals Inc.$XENE | 24.0 | $96.3M | 1,595,000 |
 Erasca, Inc.$ERAS | — | $96.2M | 5,250,000 |
 INSMED Inc$INSM | 39.4 | $69.3M | 650,000 |
 Praxis Precision Medicines, Inc.$PRAX | — | $61.9M | 185,000 |
 Alkermes plc.$ALKS | — | $58.9M | 1,125,000 |
 Oruka Therapeutics, Inc.$ORKA | — | $56.2M | 590,000 |
 ANAPTYSBIO, INC$ANAB | 48.4 | $55.8M | 826,109 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Affinity Asset Advisors, LLC's 113 positions.
Showing top 10 of 113 holdings.
Sector Allocation
Healthcare
$2.0B
Other
$16.9M
Financials
$12.8M
Full Holdings — Affinity Asset Advisors, LLC (Q2 2026)
All 113 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $ROIV | Roivant Sciences Ltd. | $132.7M | 6.5% | +34% | — |
| 2 | $APGE | Apogee Therapeutics, Inc. | $131.0M | 6.4% | -23% | — |
| 3 | $SYRE | Spyre Therapeutics, Inc. | $113.6M | 5.5% | +0% | — |
| 4 | $XENE | Xenon Pharmaceuticals Inc. | $96.3M | 4.7% | -5% | 24 |
| 5 | $ERAS | Erasca, Inc. | $96.2M | 4.7% | -2% | — |
| 6 | $INSM | INSMED Inc | $69.3M | 3.4% | +35% | 39.4 |
| 7 | $PRAX | Praxis Precision Medicines, Inc. | $61.9M | 3.0% | +9% | — |
| 8 | $ALKS | Alkermes plc. | $58.9M | 2.9% | -17% | — |
| 9 | $ORKA | Oruka Therapeutics, Inc. | $56.2M | 2.8% | +18% | — |
| 10 | $ANAB | ANAPTYSBIO, INC | $55.8M | 2.7% | -12% | 48.4 |
| 11 |  $AVTX | Avalo Therapeutics, Inc. | $53.6M | 2.6% | +116% | 11.7 |
| 12 |  $CYTK | CYTOKINETICS INC | $46.9M | 2.3% | -21% | 28.1 |
| 13 |  $RVMD | Revolution Medicines, Inc. | $46.8M | 2.3% | +150% | — |
| 14 |  $ABVX | Abivax S.A. | $44.0M | 2.1% | -19% | — |
| 15 |  $TRAX | First Tracks Biotherapeutics, Inc. | $40.9M | 2.0% | NEW | — |
| 16 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $39.0M | 1.9% | +14% | 22.6 |
| 17 |  $STRO | SUTRO BIOPHARMA, INC. | $38.9M | 1.9% | +10% | 15.3 |
| 18 |  $MRNAPUT | Moderna, Inc. | $35.0M | — | NEW | 21.2 |
| 19 |  $NUVL | Nuvalent, Inc. | $34.0M | 1.7% | -8% | — |
| 20 |  $TRVI | Trevi Therapeutics, Inc. | $33.6M | 1.6% | -10% | — |
| 21 | $MRNACALL | Moderna, Inc. | $33.3M | — | -41% | 21.2 |
| 22 | — | ARK ETF TR - GENOMIC REV ETF | $31.5M | — | NEW | — |
| 23 |  $OVID | Ovid Therapeutics Inc. | $27.3M | 1.3% | -5% | 26.4 |
| 24 |  $LXEO | Lexeo Therapeutics, Inc. | $27.0M | 1.3% | +15% | — |
| 25 |  $CLDX | Celldex Therapeutics, Inc. | $26.0M | 1.3% | +40% | 8.4 |
| 26 |  $BLTE | BELITE BIO, INC | $25.4M | 1.2% | +154% | — |
| 27 |  $ELVN | Enliven Therapeutics, Inc. | $25.4M | 1.2% | -15% | — |
| 28 |  $FBRX | Forte Biosciences, Inc. | $24.3M | 1.2% | +13% | — |
| 29 |  $LLYCALL | ELI LILLY & Co | $24.0M | — | NEW | 87.5 |
| 30 |  $NRIX | Nurix Therapeutics, Inc. | $23.5M | 1.1% | +0% | 6.4 |
| 31 |  $ANRO | Alto Neuroscience, Inc. | $22.4M | 1.1% | +70% | — |
| 32 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $21.5M | 1.1% | -27% | 40.7 |
| 33 |  $PTGX | Protagonist Therapeutics, Inc | $21.1M | 1.0% | +0% | 59.4 |
| 34 |  $MLYS | Mineralys Therapeutics, Inc. | $20.2M | 1.0% | +0% | — |
| 35 |  $RLAY | Relay Therapeutics, Inc. | $19.6M | 1.0% | +163% | 19.5 |
| 36 |  $SGMT | Sagimet Biosciences Inc. | $19.3M | 0.9% | +188% | — |
| 37 |  $JBIO | Jade Biosciences, Inc. | $18.7M | 0.9% | +31% | — |
| 38 |  $COGT | Cogent Biosciences, Inc. | $17.4M | 0.8% | -40% | — |
| 39 |  $TVTX | Travere Therapeutics, Inc. | $17.0M | 0.8% | +0% | 56.6 |
| 40 |  $CGEM | Cullinan Therapeutics, Inc. | $15.9M | 0.8% | +12% | — |
| 41 |  $SVRA | Savara Inc | $15.5M | 0.8% | +0% | — |
| 42 |  $IDYA | IDEAYA Biosciences, Inc. | $14.9M | 0.7% | NEW | 36.1 |
| 43 |  $CATX | Perspective Therapeutics, Inc. | $14.4M | 0.7% | +33% | — |
| 44 |  $ODTX | Odyssey Therapeutics, Inc. | $14.3M | 0.7% | NEW | — |
| 45 | $COGT | Cogent Biosciences, Inc. | $13.7M | 0.7% | +57% | — |
| 46 |  $OMERPUT | OMEROS CORP | $13.4M | — | NEW | — |
| 47 | — | HELIX ACQUISITION CORP III - USD CL A ORD SHS | $13.3M | 0.7% | +0% | — |
| 48 |  $EQ | Equillium, Inc. | $13.1M | 0.6% | +234% | 11.7 |
| 49 | $ALKSCALL | Alkermes plc. | $13.1M | — | NEW | — |
| 50 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $12.7M | 0.6% | +48% | 33.9 |
| 51 |  $CLYM | Climb Bio, Inc. | $12.7M | 0.6% | +39% | — |
| 52 |  $TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $12.7M | 0.6% | -73% | — |
| 53 |  $MANE | Veradermics, Inc | $12.3M | 0.6% | +43% | — |
| 54 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $12.2M | 0.6% | -25% | 38.7 |
| 55 | $OMER | OMEROS CORP | $12.2M | 0.6% | +0% | — |
| 56 |  $TSHA | Taysha Gene Therapies, Inc. | $11.9M | 0.6% | +75% | 4.9 |
| 57 |  $DMRA | Damora Therapeutics, Inc. | $11.1M | 0.5% | -6% | — |
| 58 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $10.9M | 0.5% | +4% | — |
| 59 |  $VERA | Vera Therapeutics, Inc. | $10.7M | 0.5% | +0% | — |
| 60 |  $PRQR | ProQR Therapeutics N.V. | $10.3M | 0.5% | +126% | — |
| 61 |  $NAMS | NewAmsterdam Pharma Co N.V. | $9.3M | 0.5% | +0% | — |
| 62 |  $KRRO | Korro Bio, Inc. | $9.3M | 0.5% | +0% | 14.1 |
| 63 |  $QURECALL | uniQure N.V. | $9.2M | — | -33% | — |
| 64 |  $AVR | Anteris Technologies Global Corp. | $9.0M | 0.4% | +0% | — |
| 65 |  $ZURA | Zura Bio Ltd | $8.6M | 0.4% | -43% | — |
| 66 | $QURE | uniQure N.V. | $8.1M | 0.4% | NEW | — |
| 67 |  $ASND | Ascendis Pharma A/S | $8.0M | 0.4% | -68% | 44.8 |
| 68 |  $IBIO | iBio, Inc. | $7.0M | 0.3% | +29% | 10.4 |
| 69 |  $GENB | Generate Biomedicines, Inc. | $6.7M | 0.3% | +14% | — |
| 70 |  $EVMNPUT | Evommune, Inc. | $6.6M | — | NEW | 14.9 |
| 71 |  $TYRA | Tyra Biosciences, Inc. | $6.4M | 0.3% | -22% | — |
| 72 |  $SLGL | Sol-Gel Technologies Ltd. | $6.3M | 0.3% | +143% | — |
| 73 |  $SABS | SAB Biotherapeutics, Inc. | $5.9M | 0.3% | +165% | — |
| 74 |  $MGNX | MACROGENICS INC | $5.6M | 0.3% | +143% | 39.6 |
| 75 |  $CRSP | CRISPR Therapeutics AG | $5.5M | 0.3% | -33% | 9.7 |
| 76 | $NAMS | NewAmsterdam Pharma Co N.V. | $5.3M | 0.3% | +0% | — |
| 77 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $5.2M | 0.3% | NEW | 41.5 |
| 78 |  $RZLT | Rezolute, Inc. | $5.2M | 0.3% | -35% | — |
| 79 |  $DTIL | PRECISION BIOSCIENCES INC | $5.1M | 0.3% | +8% | 10.6 |
| 80 |  $COAG | Hemab Therapeutics Holdings, Inc. | $5.1M | 0.3% | NEW | — |
| 81 |  $VRDN | Viridian Therapeutics, Inc.\DE | $4.6M | 0.2% | +0% | 27.2 |
| 82 |  $AVBP | ArriVent BioPharma, Inc. | $4.3M | 0.2% | -29% | — |
| 83 |  $VRCA | Verrica Pharmaceuticals Inc. | $4.3M | 0.2% | +0% | 32.7 |
| 84 |  $CMPS | COMPASS Pathways plc | $4.3M | 0.2% | -73% | — |
| 85 |  $MBX | MBX Biosciences, Inc. | $4.1M | 0.2% | -50% | — |
| 86 |  $RACC | Research Alliance Corp III | $4.0M | 0.2% | NEW | — |
| 87 |  $IMVT | Immunovant, Inc. | $3.9M | 0.2% | +0% | — |
| 88 |  $AMAN | Amanat Acquisition Corp. | $3.8M | 0.2% | NEW | — |
| 89 |  $BHVN | Biohaven Ltd. | $3.7M | 0.2% | NEW | — |
| 90 | — | FAETH THERAPEUTICS INC - COM NEW | $3.6M | 0.2% | NEW | — |
| 91 |  $KPTI | Karyopharm Therapeutics Inc. | $3.1M | 0.1% | -38% | 15.1 |
| 92 |  $ALEC | Alector, Inc. | $3.0M | 0.1% | +202% | 10.9 |
| 93 |  $SGP | SpyGlass Pharma, Inc. | $2.9M | 0.1% | -47% | — |
| 94 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $2.8M | 0.1% | +0% | 25.5 |
| 95 |  $OACC | Oaktree Acquisition Corp. III Life Sciences | $2.8M | 0.1% | +0% | — |
| 96 |  $CELC | Celcuity Inc. | $2.3M | 0.1% | -33% | — |
| 97 |  $JATT | JATT II Acquisition Corp. | $2.3M | 0.1% | NEW | — |
| 98 |  $NMRA | Neumora Therapeutics, Inc. | $1.8M | 0.1% | NEW | — |
| 99 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $1.8M | 0.1% | NEW | 8.7 |
| 100 |  $ANL | Adlai Nortye Group Ltd. | $1.8M | 0.1% | -7% | — |
| 101 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $1.6M | 0.1% | NEW | — |
| 102 |  $SMMTCALL | Summit Therapeutics Inc. | $1.5M | — | NEW | — |
| 103 |  $EIKN | Eikon Therapeutics, Inc. | $1.3M | 0.1% | NEW | — |
| 104 |  $OKUR | OnKure Therapeutics, Inc. | $1.1M | 0.1% | +0% | — |
| 105 |  $ENGN | enGene Therapeutics Inc. | $1.0M | 0.1% | -2% | — |
| 106 |  $XFOR | X4 Pharmaceuticals, Inc | $677,150 | 0.0% | +0% | 28 |
| 107 |  $BOLD | Boundless Bio, Inc. | $625,000 | 0.0% | NEW | — |
| 108 |  $LENZ | LENZ Therapeutics, Inc. | $568,000 | 0.0% | +0% | 12.8 |
| 109 |  $FIXX | Q32 Bio Inc. | $353,879 | 0.0% | +0% | 36.4 |
| 110 |  $OBIO | Orchestra BioMed Holdings, Inc. | $144,121 | 0.0% | -92% | 32 |
| 111 |  $NXTC | NextCure, Inc. | $67,136 | 0.0% | -83% | — |
| 112 |  $ADGM | Adagio Medical Holdings, Inc. | $52,128 | 0.0% | +0% | — |
| 113 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $278 | 0.0% | +0% | — |
New Positions (23)
$TRAX First Tracks Biotherapeutics, Inc.$40.9M$MRNAPUT Moderna, Inc.$35.0M$LLYCALL ELI LILLY & Co$24.0M$IDYA IDEAYA Biosciences, Inc.$14.9M$ODTX Odyssey Therapeutics, Inc.$14.3M$OMERPUT OMEROS CORP$13.4M$ALKSCALL Alkermes plc.$13.1M$QURE uniQure N.V.$8.1M$EVMNPUT Evommune, Inc.$6.6M$ASMB ASSEMBLY BIOSCIENCES, INC.$5.2M$COAG Hemab Therapeutics Holdings, Inc.$5.1M$RACC Research Alliance Corp III$4.0M$AMAN Amanat Acquisition Corp.$3.8M$BHVN Biohaven Ltd.$3.7MExited Positions (15)
$SPYPUT SPDR S&P 500 ETF TRUST
$CNTA Centessa Pharmaceuticals plc
$ACLX Arcellx, Inc.
$TERN Terns Pharmaceuticals, Inc.
$BMYCALL BRISTOL MYERS SQUIBB CO
$BBIO BridgeBio Pharma, Inc.
$WVE Wave Life Sciences, Inc.$RVMDPUT Revolution Medicines, Inc.
$IBRXPUT ImmunityBio, Inc.
$NVOCALL NOVO NORDISK A S$DNTHCALL Dianthus Therapeutics, Inc. /DE/
$CGONCALL CG Oncology, Inc.$CELCCALL Celcuity Inc.
$CORT CORCEPT THERAPEUTICS INC
$KZR Kezar Life Sciences, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Affinity Asset Advisors, LLC including:
Track Affinity Asset Advisors, LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Affinity Asset Advisors, LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Affinity Asset Advisors, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Affinity Asset Advisors, LLC (SEC CIK: 1773195), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Affinity Asset Advisors, LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.